158 related articles for article (PubMed ID: 6580097)
1. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.
Zimm S; Collins JM; O'Neill D; Chabner BA; Poplack DG
Clin Pharmacol Ther; 1983 Dec; 34(6):810-7. PubMed ID: 6580097
[TBL] [Abstract][Full Text] [Related]
2. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.
Balis FM; Holcenberg JS; Zimm S; Tubergen D; Collins JM; Murphy RF; Gilchrist GS; Hammond D; Poplack DG
Clin Pharmacol Ther; 1987 Apr; 41(4):384-7. PubMed ID: 3470165
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology of orally administered chemotherapy. A reappraisal.
Poplack DG; Balis FM; Zimm S
Cancer; 1986 Jul; 58(2 Suppl):473-80. PubMed ID: 3459570
[TBL] [Abstract][Full Text] [Related]
4. Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey.
Ding TL; Benet LZ
Drug Metab Dispos; 1979; 7(6):373-7. PubMed ID: 43222
[TBL] [Abstract][Full Text] [Related]
5. Effect of allopurinol on the first-pass metabolism of 6-mercaptopurine in the rat.
Sasaki H; Tsuru K; Nakamura J; Konishi R; Shibasaki J
Biochem Pharmacol; 1987 Dec; 36(23):4175-6. PubMed ID: 3689444
[No Abstract] [Full Text] [Related]
6. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
[TBL] [Abstract][Full Text] [Related]
7. Effect of allopurinol on the intestinal absorption of 6-mercaptopurine in rats.
Sasaki H; Tsuru K; Nakamura J; Konishi R; Shibasaki J
J Pharmacobiodyn; 1987 Dec; 10(12):697-702. PubMed ID: 3451956
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma.
Keuzenkamp-Jansen CW; DeAbreu RA; Bökkerink JP; Lambooy MA; Trijbels JM
J Pediatr Hematol Oncol; 1996 May; 18(2):145-50. PubMed ID: 8846126
[TBL] [Abstract][Full Text] [Related]
9. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients.
Odlind B; Hartvig P; Lindström B; Lönnerholm G; Tufveson G; Grefberg N
Int J Immunopharmacol; 1986; 8(1):1-11. PubMed ID: 3957504
[TBL] [Abstract][Full Text] [Related]
10. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
[TBL] [Abstract][Full Text] [Related]
11. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
Gerich ME; Quiros JA; Marcin JP; Tennyson L; Henthorn M; Prindiville TP
J Crohns Colitis; 2010 Nov; 4(5):546-52. PubMed ID: 21122558
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt B; Tittel M
Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
[TBL] [Abstract][Full Text] [Related]
13. Acute lymphocytic leukemia in a child with congenital xanthine oxidase deficiency: implications for therapy.
Morgan E; Honig G; Nelson DJ
Am J Pediatr Hematol Oncol; 1981; 3(4):439-41. PubMed ID: 6949480
[TBL] [Abstract][Full Text] [Related]
14. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
Brackett J; Schafer ES; Leung DH; Bernhardt MB
Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
[TBL] [Abstract][Full Text] [Related]
15. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
[TBL] [Abstract][Full Text] [Related]
16. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
Innocenti F; Danesi R; Di Paolo A; Loru B; Favre C; Nardi M; Bocci G; Nardini D; Macchia P; Del Tacca M
Cancer Chemother Pharmacol; 1996; 37(5):409-14. PubMed ID: 8599862
[TBL] [Abstract][Full Text] [Related]
17. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?
Zimm S; Collins JM; Riccardi R; O'Neill D; Narang PK; Chabner B; Poplack DG
N Engl J Med; 1983 Apr; 308(17):1005-9. PubMed ID: 6572786
[No Abstract] [Full Text] [Related]
18. The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat.
Burton NK; Aherne GW
Cancer Chemother Pharmacol; 1986; 16(1):83-4. PubMed ID: 3484383
[TBL] [Abstract][Full Text] [Related]
19. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.
Sulh H; Koren G; Whalen C; Soldin S; Zipursky A; Greenberg M
Clin Pharmacol Ther; 1986 Dec; 40(6):604-9. PubMed ID: 3465489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
